pd- blockade induces responses inhibiting adaptive immune resistance 
therapies target programmed death- pd- receptor shown unprecedented rates durable clinical responses patients various cancer types1- one mechanism cancer tissues limit host immune response via upregulation pd- ligand pd-l1 ligation pd- antigen-specific cd8+ t cells termed adaptive immune resistance7 show pre-existing cd8+ t cells distinctly located invasive tumour margin associated expression pd-/pd-li immune inhibitory axis may predict response therapy analysed samples patients metastatic melanoma obtained anti-pd- therapy pembrolizumab using quantitative immunohistochemistry quantitative multiplex immunofluorescence nextgeneration sequencing t-cell antigen receptors tcrs serially sampled tumours patients responding treatment showed proliferation intratumoral cd8+ t cells directly correlated radiographic reduction tumour size pre-treatment samples obtained responding patients showed higher numbers cd8- pd- pd-l1-expressing cells invasive tumour margin inside tumours close proximity pd- pd-l1 clonal tcr repertoire using multivariate analysis established predictive model based cd8+ expression invasive margin validated model independent cohort patients findings indicate tumour regression therapeutic pd- blockade requires pre-existing cd8 t cells negatively regulated pd- /pd-li-mediated adaptive immune resistance 
